Skip to main content
AMRN logo

Amarin Corporation plc (AMRN) Stock Price & Analysis

Amarin Corporation plc (AMRN) — MoonshotScore 21/100 (Weak band), calculated Nov 18, 2026. Price $11.26 (0.00%), as of the Nov 19, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$11.26 $0.00 (0.00%)

Amarin Corporation plc · AMRN · NASDAQ

Amarin Corporation plc is a pharmaceutical company focused on developing and commercializing therapeutics for cardiovascular diseases.

Price as of Nov 19, 2026

Key Statistics

21 of 100

MoonshotScore v2 · Amarin Corporation (AMRN)

Weak
Business Quality Solid (61)
Financial Safety Strained (35)
Valuation Cheap (90)
Growth Durability Flat (50)
Momentum Quiet (50)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Dirt-cheap, but a strained balance sheet and average growth. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Strained; Valuation: Cheap; Growth Durability: Flat; Momentum: Quiet.

  • EPS beat 0 of the last 4 reports
  • Altman Z -2.07 · Piotroski F 4
  • ROE -4.3% · ROA -3.0% · current ratio 3.50 · earnings yield -8.1% · free-cash-flow yield 30.4%

Helping: an attractive price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for AMRN (52 recorded, newest six shown)
RecordedScoreBand
20Weak
21Weak
21Weak
21Weak
21Weak
21Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$11.26
Change on the day0.00%
52-week range$11.25 – $17.31
Price / earnings (trailing)12.80
Shares traded on the day113.2K

Price & events

Other perspectives

Council score for Amarin Corporation (AMRN): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Weak
Valuation Strong
Growth Durability Neutral
Momentum Neutral

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Debt/Equity Strong
ROE Negative
Gross Margin Moderate

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Amarin Corporation (AMRN), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Amarin Corporation plc (AMRN) is listed on NASDAQ. It employs 80 people and is led by Aaron D. Berg.

2 · Latest results

What do the latest results show for Amarin Corporation (AMRN)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$50M-$8M-$0.37 (diluted)
Q4 FY2025$49M-$1M-$0.06 (diluted)
Q1 FY2026$45M-$11M-$0.50 (diluted)
Q2 FY2026$42M-$8M-$0.37 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Amarin Corporation (AMRN)?

Short answer · as of

The MoonshotScore pillars rate an attractive price as strengths. The distress and quality screens read Altman Z -2.07 · Piotroski F 4. Trailing ratios: ROE -4.3% · ROA -3.0% · current ratio 3.50 · earnings yield -8.1% · free-cash-flow yield 30.4%.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -2.07 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-4.3%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
5 · Peer comparison

How does Amarin Corporation compare with its peers?

Short answer

Amarin Corporation's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eli Lilly and Company (LLY) Same industry, near in market value$1382.75 Nov 18, 2026$1.23T98 5-pillar Nov 18, 2026
Sanofi (SNY) Same industry, near in market value$47.12 Nov 18, 2026$113B87 5-pillar Nov 18, 2026
AstraZeneca PLC (AZN) Same industry, near in market value$178.76 Nov 18, 2026$277B85 5-pillar Nov 18, 2026
Bristol-Myers Squibb Company (BMY) Same industry, near in market value$58.34 Nov 19, 2026$119B85 5-pillar Nov 18, 2026
Amgen Inc. (AMGN) Same industry, near in market value$443.89 Nov 18, 2026$240B84 5-pillar Nov 18, 2026
Johnson & Johnson (JNJ) Same industry, near in market value$272.70 Nov 18, 2026$656B83 5-pillar Nov 18, 2026
AbbVie Inc. (ABBV) Same industry, near in market value$286.01 Nov 18, 2026$506B83 5-pillar Nov 18, 2026
Novartis AG (NVS) Same industry, near in market value$155.21 Nov 18, 2026$293B82 5-pillar Nov 18, 2026
GSK plc (GSK) Same industry, near in market value$48.58 Nov 18, 2026$97.4B77 5-pillar Nov 18, 2026
Gilead Sciences, Inc. (GILD) Same industry, near in market value$168.98 Nov 18, 2026$210B72 5-pillar Nov 18, 2026
Merck & Co., Inc. (MRK) Same industry, near in market value$137.78 Nov 18, 2026$340B69 5-pillar Nov 18, 2026
Pfizer Inc. (PFE) Same industry, near in market value$28.06 Nov 18, 2026$160B67 5-pillar Nov 18, 2026
Amarin Corporation (AMRN) — this page$11.26—21

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Aug 1, 2026

Transactions
18
Identified insiders
5
Purchases
0
Sales
0
Other transactions
18

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held AMRN in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported AMRN in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Amarin Corporation (AMRN)?

Read these with our analysis →

Investor Questions: AMRN Stock

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

What does the MoonshotScore mean for AMRN?

AMRN carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is AMRN a good stock to buy?

Stock Expert AI does not rate AMRN buy, sell or hold. Amarin Corporation plc carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the AMRN stock price today?

The last price recorded for Amarin Corporation plc (AMRN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the key factors to evaluate for AMRN?

Amarin Corporation plc (AMRN) holds a MoonshotScore in the low range. To weigh it, start with the trailing P/E under Price & valuation on this page. VASCEPA offers a targeted solution in this specific patient cohort. Not financial advice.

How frequently does AMRN data refresh on this page?

AMRN's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven AMRN's recent stock price performance?

Amarin Corporation plc (AMRN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider AMRN overvalued or undervalued right now?

The trailing P/E of Amarin Corporation plc (AMRN) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research AMRN before investing?

Before investing in Amarin Corporation plc (AMRN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding AMRN to a portfolio?

No dossier-level strength is on record for Amarin Corporation plc (AMRN) yet — start from the MoonshotScore factor breakdown and the Financials tab on this page. Weigh rewards against risks and diversify. Not financial advice.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 13 figures on this page — 7 from Financial Modeling Prep (FMP), 5 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.